Cited by 188Global Cancer Incidence and ScreeningProstate Cancer Diagnosis and TreatmentLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

Welch, H. Gilbert, Gorski, David H., Albertsen, Peter C.·2015·New England Journal of Medicine

DOI 10.1056/nejmp1510443

Open this paper in CoChat — free account

Abstract

Interview with Dr. H. Gilbert Welch on trends in the incidence of metastatic cancers and their implications for both screening and our understanding of cancer. (06:57)Download Discordant trends in the incidence of metastatic breast and prostate cancer since the widespread implementation of early-detection efforts may reflect distinct disease dynamics or may result from the different screening strategies used.

Integrity signals

Registry

Crossref · 10.1056/nejmp1510443

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prostate-Cancer Mortality at 11 Years of Follow-up
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., KWIATKOWSKI, M. K., Lujan, M., Lilja, H. G., Zappa, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113135 · Cited by 1,241
Impact of Follow-up Testing on Survival and Health-Related Quality of Life in Breast Cancer Patients
Ghezzi, P. (1994) · JAMA · doi:10.1001/jama.1994.03510440047031 · Cited by 618
Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005
Welch, H. G., & Albertsen, P. C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp278 · Cited by 578
Self-citation
Karnofsky Memorial Lecture. Natural history of small breast cancers.
Hellman, S. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2229 · Cited by 414
TEMPORAL TRENDS IN RATES OF PROSTATE CANCER: DECLINING INCIDENCE OF ADVANCED STAGE DISEASE, 1974 TO 1994
Newcomer, L. M., Stanford, J. L., Blumenstein, B. A., & Brawer, M. K. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64231-9 · Cited by 158

Show all 5 references

Sorted by citations

Items 101–188 of 188

Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)–Medicare Registry
Fairweather, M., Jiang, W., Keating, N. L., Freedman, R. A., King, T. A., & Nakhlis, F. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4689-y · Cited by 8
Impact of COVID-19 pandemic on screening and diagnosis of patients with prostate cancer: a systematic review protocol
Zadeh, S. M. M., Tajik, F., Moradi, Y., Kiani, J., Ghods, R., & Madjd, Z. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063748 · Cited by 7
An exploration for quantification of overdiagnosis and its effect for breast cancer screening
Yang, L., Wang, S., & Huang, Y. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2020.01.04 · Cited by 7
Is prostate cancer stage migration continuing for black men in the PSA era?
Dobbs, R. W., Greenwald, D. T., Wadhwa, H., Freeman, V. L., & Abern, M. R. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.68 · Cited by 7
Germline mutations and prostate cancer: is it time to change treatment algorithms?
Telvizian, T., & Mukherji, D. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-19-207 · Cited by 6
Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer
Chung, D. Y., Kim, M. S., Lee, J. S., Goh, H. J., Koh, D. H., Jang, W. S., Hong, C., & Choi, Y. D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040542 · Cited by 6
Precision management of localized prostate cancer
VanderWeele, D. J., Türkbey, B., & Sowalsky, A. G. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1267562 · Cited by 6
Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation.
Olsson, C. A., Lavery, H. J., Yadav, K. K., Anderson, A. E., & Kapoor, D. A. (2018) · PubMed Central · doi:10.3909/riu0815 · Cited by 6
Rising metastatic prostate cancer rates but narrowing racial gap
Zurl, H., Qian, Z., Pohl, K. K., Piccolini, A., Korn, S. M., Labban, M., Lipsitz, S. R., Cho, M., Fletcher, S. A., Leitsmann, M., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04448-6 · Cited by 5
Cancer dynamics and the success of cancer screening programs
Diamandis, E. P. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1201 · Cited by 5
Prevention of breast cancer by RANKL/RANK blockade
Galluzzi, L., Buqué, A., & Kroemer, G. (2016) · Cell Research · doi:10.1038/cr.2016.79 · Cited by 5
Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood
Maj‐Hes, A., Sevcenco, S., Szarvas, T., & Kramer, G. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0888-0 · Cited by 5
Advances in the diagnostic options for prostate cancer
French, W. W., & Wallen, E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1822067 · Cited by 5
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition
Santis, F. D., Fucà, G., Schadendorf, D., Mantovani, A., Magnani, L., Lisanti, M. P., Pettitt, S. J., Bellone, M., Sal, G. D., Minucci, S., et al. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.02.001 · Cited by 5
Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer
Fischer-Valuck, B. W., Rao, Y. J., Brenneman, R., Patel, P. R., Filson, C. P., Jani, A. B., Liu, Y., Goyal, S., Xu, K., Weiss, A. D., et al. (2020) · Brachytherapy · doi:10.1016/j.brachy.2020.05.007 · Cited by 4
Analyzing Factors Enabling Prostate Cancer Screening Behaviors Among African American Males in the South Region Using the Andersen’s Behavioral Model of Healthcare Services Utilization
Kim, Y., & Alhassan, M. (2023) · Journal of Prevention · doi:10.1007/s10935-023-00722-6 · Cited by 4
Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy
Taylor, M. A., Mehrdad Alemozaffar, A., Master, V. A., Sanda, M. G., & Filson, C. P. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.01.012 · Cited by 4
Closing the Loop on the Role of Multiparametric Magnetic Resonance Imaging–Targeted Prostate Biopsy
Shabsigh, A., & Lee, C. T. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1735 · Cited by 4
Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence
Lautert-Dutra, W., Melo, C. M., Chaves, L. P., Souza, F. C. M., Crozier, C., Sundby, A. E., Woroszchuk, E., Saggioro, F. P., Avante, F. S., dos Reis, R. B., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280943 · Cited by 4
News Media Analysis of the United States Preventive Services Task Force and American Urological Association Prostate Cancer Screening Guidelines
Koo, K., Shee, K., & Yap, R. L. (2016) · Urology Practice · doi:10.1016/j.urpr.2016.12.001 · Cited by 4
Cancer, circulating tumor cells, and metastasis: could protein-derived peptide fragments impede brain metastases?
Mizejewski, G. J. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.20 · Cited by 4
Sucesso do Outubro Rosa no Brasil: uma boa notícia para o controle do câncer de mama no país?
Migowski, A. (2021) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00247121 · Cited by 4
The Role of Ion Channels and Chemokines in Cancer Growth and Metastasis: A Proposed Mode of Action Using Peptides in Cancer Therapy
Mizejewski, G. J. (2024) · Cancers · doi:10.3390/cancers16081531 · Cited by 3
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer
Lorenzo, G. D., Pagliuca, M., Perillo, T., Benincasa, A., Bosso, D., Placido, S. D., & Buonerba, C. (2016) · Medicine · doi:10.1097/md.0000000000002754 · Cited by 3
Germline genetics in localized prostate cancer
Ryan, S. T., Nguyen, V., Bree, K. K., Holst, D. D., & Kader, A. K. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000648 · Cited by 3
Estimação do Sobrediagnóstico no Rastreamento Mamográfico: uma Avaliação Crítica
Migowski, A., Nadanovsky, P., & Vianna, C. M. D. M. (2021) · Revista Brasileira de Cancerologia · doi:10.32635/2176-9745.rbc.2021v67n2.1281 · Cited by 3
Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer
Sweeney, C. J. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.03.008 · Cited by 3
Evaluation of Prostate Needle Biopsies
Giannico, G. A., & Hameed, O. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_4 · Cited by 3
BIOLOGY OF BREAST CANCER
Имянитов, Е. Н. (2017) · Practical oncology · doi:10.31917/1803221 · Cited by 5
Prostate Cancer
Beheshti, M., Schöder, H. M., Walz, J. C., Rezaee, A., & Langsteger, W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48567-8.00010-9 · Cited by 3
Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy
Bellone, M., & Caputo, S. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-16624-3_8 · Cited by 3
Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
Doğan, İ., Aksoy, S., Çakar, B., Başaran, G., Erçelep, Ö., Mandel, N. M., Korkmaz, T., Gökmen, E., Sener, B. C., Aydıner, A., et al. (2023) · Cancers · doi:10.3390/cancers15061667 · Cited by 7
Menopausal hormone therapy and national time trends in mortality: cautions regarding causal inference
Manson, J. E., Bassuk, S. S., Merz, C. N. B., & Kaunitz, A. M. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000886 · Cited by 3
Câncer de Próstata: análise de sobrevida e fatores prognósticos por faixa etária de diagnóstico
Zardeto, H. N., Schmidt, T. P., & Schneider, I. J. C. (2022) · Research Society and Development · doi:10.33448/rsd-v11i8.31344 · Cited by 2
Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain
Sanvisens, A., Vidal‐Vila, A., Puigdemont, M., Viñas, G., Roqué, A., Barco, S. D., Pérez-Bueno, F., Trallero, J., Marcos‐Gragera, R., & Renart, G. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07704-8 · Cited by 2
Divergent Responses to Mammography and Prostate-Specific Antigen Recommendations
Martinez, K. A., & Rothberg, M. B. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.01.035 · Cited by 2
Prostate Cancer Screening Behavior Based on the Health Belief Model in Men Aged Over 40 Years
Kalani, L., Aghababaeian, H., Nosratabadi, M., Masoudiyekta, L., Mirsamiyazdi, N., Rezaei-Bayatiyani, H., & Ghahfarokhi, M. M. (2022) · Trends in Medical Sciences · doi:10.5812/tms-119524 · Cited by 2
The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study
Weiner, A. B., Tsai, K. P., Keeter, M.-K., Victorson, D. E., Schaeffer, E. M., Catàlona, W. J., & KUNDU, S. D. (2018) · The Journal of Urology · doi:10.1016/j.juro.2018.05.093 · Cited by 2
Are Ocular and Ocular Adnexal Cancers Overdiagnosed? Historical Perspectives on Diagnosis
Margo, C. E. (2016) · Cancer Control · doi:10.1177/107327481602300201 · Cited by 2
How to Counsel Men About PSA Screening.
Lin, K. W., & Ebell, M. H. (2016) · PubMed · Cited by 2
Breast cancer incidence as a function of the number of previous mammograms: analysis of the NHS screening programmePreprint
Corcos, D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/238527 · Cited by 2
Moving toward a more rational, evidence‐based approach to PSA screening, diagnosis, and treatment of prostate cancer
Filson, C. P. (2018) · Cancer · doi:10.1002/cncr.31332 · Cited by 2
Populatıon-based breast cancer screenıng program ın Turkey: Priliminary results
Oktay, A., Kara, F., Keskinkılıç, B., Turkyilmaz, M., Unlu, F., Dundar, S., Arıbal, E., & Gültekin, S. (2022) · International Journal of Epidemiology and Health Sciences · doi:10.51757/ijehs.3.2.2022.248388 · Cited by 1
Prostate cancer - risk factors and prevention strategies
Rybak, J., Magiera, B., & Magiera, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.21.01.018 · Cited by 1
Prostate Specific Antigen Screening on a Nationwide Level: Featuring the Contribution of Race and Life Expectancy in Decision Making
Dalela, D., Corsi, N. J., Bronkema, C., Sood, A. K., Arora, S., Majdalany, S. E., Butaney, M., Jamil, M. L., Li, P., Palma‐Zamora, I., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.11.009 · Cited by 1
The issue of prostate cancer screening
Zachoval, R., Dušek, L., & Babjuk, M. (2018) · Česká urologie · doi:10.48095/cccu2018004 · Cited by 1
Screening mammography: sparing the emperor's blushes
Niraula, S. (2016) · Cancer Medicine · doi:10.1002/cam4.859 · Cited by 1
Das Für und Wider des PSA-Screenings im Wandel der Zeit
Weißbach, L., & Roloff, C. (2017) · Uro-News · doi:10.1007/s00092-017-1593-4 · Cited by 1
The Great Breast Cancer Screening Conundrum
Desai, A. P., & Mathew, A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1731859 · Cited by 1
Conquering Metastatic Breast Cancer
Davidson, N. E. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009167 · Cited by 1
Prostate cancer: what is the right message?
Glina, S., & Pasternak, J. (2015) · Einstein (São Paulo) · doi:10.1590/s1679-45082015ed3595 · Cited by 1
Should We Fear Folate?
Downer, M. K., Blarigan, E. L. V., Peisch, S. F., & Stampfer, M. J. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.004 · Cited by 1
Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7
Nordström, T., Eklund, M., & Grönberg, H. (2016) · World Journal of Urology · doi:10.1007/s00345-016-1907-2 · Cited by 1
Defining Quality in Medical Practice [Letter To The Editor]
Boggs, N. E. (2016) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1454682635 · Cited by 1
Risk Factors for Prostate Cancer: Which Are Truly Predictive of Clinically Significant Disease?
Albertsen, P. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4742 · Cited by 1
Self-citation
Clinical Research in Practice: Th e Journal of Team Hippocrates
Boggs, N. E. (2016)
Commentary: Prostate cancer screening—A long run for a short slide
Parnes, H. L. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.02.011
Margin Reduction in Prostate Radiation Therapy
Oates, R. (2017) · Figshare · doi:10.4225/03/59826a53afaf7
La médecine nucléaire en onco-urologie – Session 3
Toch, S.-R. (2017) · Médecine Nucléaire · doi:10.1016/j.mednuc.2017.07.005
Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance
Albertsen, P. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-42603-7_72-1
Self-citation
Prävention muss effizienter werden
Porzsolt, F., Wambo, G. O. K., Rösch, M.-C., & Weiß, C. (2017) · Frauenheilkunde up2date · doi:10.1055/s-0043-115678
Preventing overdiagnosis in mammography screening – a public health perspective
Concin, H., & Nagel, G. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0040
¿Está la urología española de 2018 lo suficientemente madura para realizar cribado poblacional de cáncer de próstata?
Escandón, A. S., & Mata, J. L. (2017) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2017.11.003
Les bases de données médicales et les innovations technologiques peuvent améliorer la pertinence du diagnostic précoce du cancer de la prostate
Richard, F., Renard-Penna, R., & Mozer, P. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30159-1
William Halsted and Prostate Cancer Progression
Albertsen, P. C. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.007
Self-citation
Clinical Subtype, Treatment Response, and Survival in De Novo and Recurrent Metastatic Breast CancerPreprint
File, D. M., Pascual, T., Deal, A. M., Wheless, A., Perou, C. M., Dees, E. C., & Carey, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1479039/v1
Is Spanish urology in 2018 mature enough to perform population screening for prostate cancer?
Escandón, A. S., & Mata, J. L. (2018) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2018.03.001
Natural History of Untreated Localized Prostate Cancer: Rational for Active Surveillance
Albertsen, P. C. (2019) · Springer eBooks · doi:10.1007/978-3-319-42623-5_72
Self-citation
Author Reply
Kim, S. P. (2016) · Urology · doi:10.1016/j.urology.2016.06.069
Editorial Comment
Albertsen, P. C. (2021) · The Journal of Urology · doi:10.1097/ju.0000000000001601.01
Self-citation
Reply by Authors
Nguyen, D., Haeuser, L., Paciotti, M., Reitblat, C. R., Cellini, J., Lipsitz, S. R., Kibel, A. S., Choudhury, A. D., Cone, E. B., & Trinh, Q. (2021) · The Journal of Urology · doi:10.1097/ju.0000000000001601.02
Früherkennung von Prostatakrebs
Boedefeld, E. A. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_77-1
Are Prostate Cancer Screenings Performed in Compliance with Cancer Guidelines?
Nalbant, İ., Benli̇, E., ÇIRAKOĞLU, A., KELEŞ, M., Yazıcı, İ., & Acet, A. A. (2023) · MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE · doi:10.19127/mbsjohs.1184893
Our clinical experiences in patients with de novo and secondary metastatic breast cancers
Taşçı, H. İ., Alkan, S., & Varman, A. (2023) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.21541
Prävention und Früherkennung von Brustkrebs
Giersiepen, K. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_74-1
Prävention und Früherkennung von Brustkrebs
Giersiepen, K. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_74-2
Do screening mammograms in women aged 70 and older improve stage at diagnosis or breast cancer–specific mortality?
Levy, B. S. (2023) · OBG Management · doi:10.12788/obgm.0314
Avaliação da Expressão das Células NK no Câncer de Próstata após Prostatectomia Radical
Neto, J. A. C., de Almeida, M. S., Motta, I. A., Pereira, V. L. D. O., Alves, R. S., & Café, L. E. (2023) · Revista Científica Hospital Santa Izabel · doi:10.35753/rchsi.v7i4.457
Urologische Vorsorge
Sonntag, U., & Weckermann, D. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21442-4.00032-2
The Story of Breast and Prostate Cancer: Parallels and Common Controversies
Avolio, P. P., Giovanni Lughezzani, A., & Sánchez-Salas, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-66754-1_2
Case Studies
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.016
Case Study: Cancer Screening
Schmaling, K. B., & Kaplan, R. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009391733.019
Correcting Decades of Misinformation About Breast Cancer Screening: An Open Letter to Women and Those Who Advise Them About Screening for Breast Cancer
Kopans, D. B. (2025) · Journal of Breast Imaging · doi:10.1093/jbi/wbaf030
Investigating initial patterns of progression on first-line treatment in patients with de novo metastatic breast cancer
Huber, E. C., Gupta, G. P., Morse, R., Abdou, Y. G., Aldrich, J. D., Carey, L., Dees, E. C., Ray, E. M., Reeder-Hayes, K., Jones, E. L., et al. (2026) · Breast Cancer Research and Treatment · doi:10.1007/s10549-026-07933-5
PGC-1α régule un programme onco-métabolique capable de réprimer l’agressivité du cancer de la prostate
Kaminski, L. (2018) · theses.fr (ABES) · doi:10.70675/7f6ae88bz4f3cz49d3zafcdz8682254b2be3
Caractérisation des fonctions génomiques de variants du récepteur des androgènes dans le cancer de la prostate
Madi-Berthélémy, P. O. (2018) · theses.fr (ABES) · doi:10.70675/451e797fz4661z4896z886bz419b6d675751
Vroegopsporing van longkanker met lage dosis CT en focus op hoog-risicogroepen: toetsing aan de criteria van Wilson & Jungner
Theuns, C., Gerris, A., MEERBEECK, J. V., Hal, G. V., Lepeleire, J. D., & SNOECKX, A. (2026) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.82.25.122a
Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study
Ding, N., Geurts, S. M. E., Vriens, I. J. H., Visserman, R., van Nijnatten, T. J. A., Smidt, M. L., Voogd, A. C., Verloop, J., & Tjan‐Heijnen, V. C. G. (2026) · The Breast · doi:10.1016/j.breast.2026.104888

Authors: Welch, H. G., Gorski, D. H., & Albertsen, P. C.
Affiliations: Dartmouth Institute for Health Policy and Clinical Practice (US)
ORCID: Welch, H. Gilbert
Gorski, David H.
Albertsen, Peter C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-10-29
Volume: 373
Issue: 18
Pages: 1685-1687
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmp1510443
OpenAlex: W2288757641
Cited by: 188
References: 5
Citations by year: 2026: 3 · 2025: 5 · 2024: 7 · 2023: 13 · 2022: 15 · 2021: 11 · 2020: 18 · 2019: 18 · 2018: 19 · 2017: 39 · 2016: 37 · 2015: 2
FWCI: 14.13
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: metastatic breast cancer, metastatic prostate cancer, cancer incidence trends, cancer screening, early detection, disease dynamics
MeSH terms: Adult, Breast Neoplasms, Female, Humans, Male, Mammography, Middle Aged, Neoplasm Metastasis, Prostatic Neoplasms, United States, Incidence, Prostate-Specific Antigen, SEER Program, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks